Eli Lilly and Co. reported that 31% of 236 patients showed a 50% reduction in chronic lower-back pain after taking once-daily doses of Cymbalta in a study of the depression drug. Only 19% of patients who got placebo reported the same effect, according to the study. The company, which presented the data during a conference in Spain, is seeking FDA approval to market Cymbalta for treating chronic pain.

Related Summaries